Uses
1,1''-(4,4'',5,5''-Tetrachloro[1,3''-bi-1H-pyrrole]-2,2''-diyl)bis[1-(2-hydroxyphenyl)methanone] is a marine anticancer compound. Also, it possesses anti-bacterial properties against methicillin-resistant Staphylococcus aureus.
Definition
ChEBI: (-)-marinopyrrole A is a member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities. It has a role as an antimicrobial agent, an antibacterial agent, an antineoplastic agent, a marine metabolite and a bacterial metabolite. It is a member of pyrroles, an organochlorine compound, a member of phenols and an aromatic ketone.
Biological Activity
marinopyrrole a is a selective inhibitor of mcl-1 with ic50 value of 10.1μm [1].marinopyrrole a is a natural product froma species of marine-derived streptomycetes and is reported to be an antagonist of mcl-1. mcl-1 is a member of the anti-apoptotic bcl-2 family, which is a well-validated drug target for cancer treatment. nmr titration experiments show that marinopyrrole a can directly interact with mcl-1. it can prevent bim-bh3 peptides from binding to mcl-1 but not bcl-xl. the cell based assay shows a high selectivity of marinopyrrole a. treatment with marinopyrrole a inhibit the viability of k562 cells transfected with mcl-1 gene with ec50 value of 1.6μm. the selectivity is more than 40-fold greater over the cells transfected with bcl-xl gene. moreover, marinopyrrole a can decreases mcl-1 expression by increasing the cleavage of caspase-3 and parp. marinopyrrole a is also reported to completely restore the sensitivity of multidrug resistant leukemia cells to abt-737 [1].
References
[1] doi k, li r, sung ss, et al. discovery of marinopyrrole a (maritoclax) as a selective mcl-1 antagonist that overcomes abt-737 resistance by binding to and targeting mcl-1 for proteasomal degradation. j biol chem. 2012 mar, 287(13): 10224-35.
